Long-Term Benefits of Percutaneous Anatomical Restoration of Vertebral Compression Fractures Linked to Malignancy

David Cesar NORIEGA¹, Antonio KRÜGER², Ruben Hernandez RAMAJO¹, Francisco ARDURA¹, MariFe MUNOZ³, Soner SAHIN⁴

¹Valladolid University Hospital, Spine Unit, Department of Orthopedic, Valladolid, Spain
²Marburg University, Department of Trauma, Marburg, Germany
³Valladolid University Hospital, Department of Investigation, Valladolid, Spain
⁴Derince Research and Teaching Hospital, Department of Neurosurgery, Kocaeli, Turkey

ABSTRACT

AIM: To evaluate the efficacy, feasibility and safety of a percutaneous anatomical vertebral body reduction for the treatment of VCF (vertebral compression fracture) linked to malignancy. Vertebroplasty and percutaneous kyphoplasty have played essential roles in the treatment of painful vertebral metastasis, although there are few reports with long survival that have evaluated the long-term efficacy, adjacent fractures and vertebral body (VB) re-collapse associated with these procedures. We aimed to evaluate the long-term efficacy and the complications associated with malignancy and changes in spinal biomechanics.

MATERIAL and METHODS: The retrospective study examined 32 patients with osteolytic VCF due to malignant infiltration of the vertebral body. A visual analogue scale, the EQ5 and radiological analysis (i.e., X-ray and CT scan) were used to assess back pain, quality of life and complications.

RESULTS: Statistically significant reductions in anterior and central vertebral body heights (6.2 mm-19.6 ± 4.2 mm- and 5.8 mm-16.7 ± 7.8 mm-, respectively) that resulted in reductions of the regional Cobb angles exceeding 30% were observed. There was also a statistically significant improvement in quality of life. The average survival was longer than those reported in most published articles, and the average follow-up period was 30.9 months.

CONCLUSION: Anatomical restoration (i.e., cortical ring reduction with endplate rebalancing) is potentially beneficial for a well-selected group of patients with spine metastases and long life expectancies because this procedure avoids the complications typical of these types of treatments (e.g., leakage, adjacent fractures and re-collapse).

KEYWORDS: Percutaneous anatomical restoration, PMMA, Spine VCF, Malignant disease, Minimally invasive procedure

INTRODUCTION

Spine disease due to malignant lesions is common among cancer patients. The incidence of spine malignant disease varies from 30% to 70%, depending on the primary tumor (14,30), although not all of these cases are symptomatic. The incidence of vertebral compression fracture (VCF) in multiple myeloma is 24%, 14% in breast cancer and 6% among prostate cancer. Approximately 10% of lung cancer patients will develop spine symptoms, and approximately 40% to 70% of these patients will have multiple-level involvement (1,28,34).

The development of VCF associated with malignancy deteriorates quality of life and increases pain, sagittal imbalance and abdominal and respiratory problems (2,41). All of these symptoms are of great importance when dealing with the osteoporotic population (18) and are even more relevant for the cancer population (13,19,20,22,33).
The biomechanical changes that occur after a VCF predispose the maintenance an increase of clinical problems, such as chronic pain, respiratory pathology (9,37,40) and abdominal disease accompanied by the development of early satiety (36). Thus, attending to these types of problems in cancer patients is particularly important to avoid respiratory infections or deterioration in the quality of life due to the previous weight loss and immunosuppression that they may have suffered.

Previous publications have focused on pain treatment in this group of patients (32) and not on evaluations of methods to control the biomechanical changes and the clinical consequences of these changes (9,37,40). Due to an increase in the life expectancy of this group of patients (3,7,10,19,20), these biomechanical changes are increasingly likely to occur and result in clinical symptoms.

Given our current knowledge, does it make sense to plan anatomical restorative treatments for patients with VCFs related to cancer?

The objective of this clinical study was to analyze whether anatomical restorations (i.e., cortical height reduction and endplate reduction) of VCFs caused by malignant lesions affect pain control and clinico-radiological complications over a long-term follow-up.

### MATERIAL and METHODS

A retrospective study from January 2009 to December 2012 that included all patients who underwent surgery for malignant VCF was performed under the approval of the Ethics Committee of our institution.

During the period of the study, 32 consecutive patients with osteolytic malignant disease of the spine who had a VCF underwent surgeries that were performed on a total of 52 vertebral levels. There were 18 males and 14 females in our sample. The average time between the cancer diagnosis and the occurrence of the VCF was 25.9 months (0-164). A total of 52 levels were involved, and the hematologic group contained a greater number of patients who were affected on multiple levels; 62.5% of the patients with multiple level involvement belonged to this group, but the difference between these groups was not statistically significant (p=0.12). The thoracolumbar junction was the most affected area in both groups and at both the single and multiple levels (Table I).

The average follow-up time was 19.7 months (2-50).

Fourteen patients had a hematologic disease; 9 cases had multiple myeloma, and 5 cases had lymphoma. In the other 18 patients, the primary tumors were in the lung (1 case), gastrointestinal (7 cases), melanoma (1 case), in the breast (3 cases), seminoma (1 case), mesothelioma (1 case), in the bladder (1 case), and in the prostate (3 cases). The vertebral segments most frequently affected were T12 and L1 in both groups.

### Surgical Technique

Anatomical restorations were achieved via minimally invasive cementoplasty surgery, which consists of reducing both the cortical ring and the endplate of the vertebra through the introduction of two titanium cranio-caudal expandable implants (SpineJack®, Vexim SA, Balma, France) (Figure 1) into the vertebral body through a transpedicular approach, under general anesthesia, to reposition the end plate fragments into their anatomical positions to achieve a full correction of the vertebral body and to control biomechanical changes in the spine. Posterior fixation was accomplished with high viscosity polymethyl methacrylate (PMMA) cement (400 Pa) with zirconium oxide to improve visibility (Figure 2A-C) (26,27).

### Evaluation of Results

The outcome measures used to evaluate our results are detailed below:

1. The efficacy of the procedure across the entire group was evaluated using visual analogue scale (VAS) pain score: preoperative and postoperative, at 12 months follow-up, and at final follow-up.
2. EQ5 quality of life: preoperative and at 6- and 12 months follow-up.

![Table I: Single and multiple VCF distributions by levels. (YES= multilevel / NO= single level).](image-url)
4. Radiological analyses via standing X-ray in both the anteroposterior (AP) and lateral planes and preoperative-postoperative height definition computed tomography (CT) scans (1 mm slices) including the following:
   a. anterior height
   b. central height
   c. posterior height
5. Regional Cobb angle (2 vertebrae above - 2 vertebrae below).
6. Complications: Cement leakage, adjacent fractures, and vertebral body re-collapse.

**Statistical Analyses**

The normalities of the distributions of the parameters were first analyzed with Shapiro-Wilk tests. All quantitative parameters are described with averages and standard deviations, and the qualitative values are described as frequency distributions. Pearson chi-square tests were used to evaluate the associations between qualitative parameters. Comparisons of pain evolution between the preoperative (preop) and postoperative (postop) check-ups were performed with t-tests. ANOVAs were used to assess changes in pain along the four clinical controls and were performed along the period of study (i.e., preop., postop., 1 year and final follow-up). All data were analyzed with the SPSS statistical software package (version 20.0). p<0.05 was considered statistically significant.

**RESULTS**

**Pain Scores**

The average preop VAS value was 7.15, the average postop VAS value was 1.81, the average 12-month follow-up VAS value was 1.94 and the average final follow-up VAS value was 2.24. The differences between the preop, postop, 12-month and final follow-up values were statistically significant (p<0.001).

The preop VAS score (7.07) of the hematologic patients was decreased (1.88) at the first postop check-up, remained stable at the 1-year follow-up and increased slightly (2.24) at the final follow-up (22.75 months). The differences between the preop, postop and 12-month follow-up values were statistically significant (Table II).

**Figure 1: SpineJack® Procedure.**

Implant placement – Implant deployment – Cement Injection.

**Figure 2: Breast-cancer metastasis in T12. A.1.2 fracture. X-rays at A) Preop B) Postop and C) Final check-up.**
The mean preop VAS score of the metastatic patients was 7.23. Pain decreased to 1.75 at the immediate postop, increased to 2.09 at the 12-month follow-up and increased to 2.23 at the final follow-up. The difference between the preop and postop values was statistically significant (p<0.001) (Table II).

**Quality of Life**

The average preoperative EQ5-VAS value was 22.3 (20.1-26.3), and this value significantly (p<0.005) increased to 68.9 (66.7-71.1) at the 6-month follow-up. At the 12-month follow-up, the quality of life decreased to an average of 65.6 (63.2-68.3) (Table III).

**Survival**

The average survival of the entire group was 30.9 months with a confidence interval (95%) of 24.2-37.7. The hematologic group of patients had an average survival of 38.3 with a confidence interval (95%) of 29.6-47, and the metastasis group had an average survival of 22.8 with a confidence interval (95%) of 15.9-29.7 (Table IV).

Three patients died within the first 2-6 months after VCF. In total, 13 patients died across the period of study, and their average follow-up time was 14.9 (2-36) months. The remaining 19 patients had 33 VCFs and, at present, are still alive and actively being followed up. The current follow-up time is 21.2 (6-50) months.

**Height Restoration Analyses**

The average preoperative anterior height of the vertebral body was 19.6 ± 4.2 mm. This anterior height increased an average of 6.2 mm (31.6%) postoperatively, and this increase was stable over the follow-up period as evidence by the average height of 25.5 mm at the 12-month follow-up. The differences between the preop, postop and 12-month heights were statistically significant (p<0.01) (Table V).

The average preoperative central height was 16.7 ± 7.8 mm. Postoperatively, this height increased by 5.8 mm (34.7%), which reflected a statistically significant difference (p<0.001). This increased height remained stable at the 12-month follow-up (Table V).

The mean preop VAS score of the metastatic patients was 7.23. Pain decreased to 1.75 at the immediate postop, increased to 2.09 at the 12-month follow-up and increased to 2.23 at the final follow-up. The difference between the preop and postop values was statistically significant (p<0.001) (Table II).

**Quality of Life**

The average preoperative EQ5-VAS value was 22.3 (20.1-26.3), and this value significantly (p<0.005) increased to 68.9 (66.7-71.1) at the 6-month follow-up. At the 12-month follow-up, the quality of life decreased to an average of 65.6 (63.2-68.3) (Table III).

Three patients died within the first 2-6 months after VCF. In total, 13 patients died across the period of study, and their average follow-up time was 14.9 (2-36) months. The remaining 19 patients had 33 VCFs and, at present, are still alive and actively being followed up. The current follow-up time is 21.2 (6-50) months.

**Height Restoration Analyses**

The average preoperative anterior height of the vertebral body was 19.6 ± 4.2 mm. This anterior height increased an average of 6.2 mm (31.6%) postoperatively, and this increase was stable over the follow-up period as evidence by the average height of 25.5 mm at the 12-month follow-up. The differences between the preop, postop and 12-month heights were statistically significant (p<0.01) (Table V).

The average preoperative central height was 16.7 ± 7.8 mm. Postoperatively, this height increased by 5.8 mm (34.7%), which reflected a statistically significant difference (p<0.001). This increased height remained stable at the 12-month follow-up (Table V).
DISCUSSION

Cancer treatment and diagnosis has evolved in the past decade, and this evolution has increased the life expectancy and quality of life of patients (19,20). Vertebral compression fractures related to cancer infiltration of the vertebral body are a major problem for this group of patients because they cause severe deterioration in quality of life (34). The cementoplasty technique has been widely used for pain control, but complications from either VP or KP, although uncommon, can be serious. Both techniques are efficient, but focus on controlling pain and not on controlling the biomechanical consequences of VCF (1,14,20,32). Kyphoplasty, compared with conservative treatment or vertebroplasty, allows at best an additional restoration of the vertebral height and of the kyphosis angle (16). Both Verlaan and Voggenreiter have demonstrated that part of the restored height is lost when deflating the balloon prior to the cement injection (38, 39). Therefore, new methods like this intravertebral implant technique, have a clear advantage in keeping the height restoration until the stabilizing cement has been injected. Also a direct action on the endplates would be desirable to restore anatomy instead of relying on the ligamentotaxis effect.

Pain control has been the primary objective of all previous studies. In this study pain was reduced by an average of 5.3 postoperatively and 4.9 at the final follow-up (p<0.005). This reduction of 74% is within the range of the results of the majority of previously published articles (12, 25, 29, 32) at 1-month follow-ups. At the 6-month follow-up, the results remained stable (5, 21); our study entailed longer follow-up periods for the majority of the patients (i.e., 38.2 months for the hematologic and 22.8 for the metastatic patients).

Dudeney (10) reported improvements in the bodily pain of 18 myeloma patients as measured by SF36 (10), but the follow-up period of this study averaged only 7.4 months. Eleraky et al. (11) reported a VAS score improvement of 4.9 at the 12-month follow-ups of a retrospective group of 14 patients.
with 30 vertebra body levels involved. Georgy (14) only reported leakage in 28 malignant VCFs and did not mention VAS scores. Zhonglai (41) followed patients for 2 years and found an average improvement of 3.6 on the VAS that was stable throughout the follow-up period of that study. At the end of our study (June 2013), the improvements in the VAS remained unchanged in the series and statistically improved compared to the preop values.

The quality of life of our group of patients, as measured with the EQ-5-VAS, increased from 22.3 to 68.9 at the 6-month follow-up (p<0.005). At the 12-month follow-up, the quality of life was reduced to 65.6; this reduction was mainly attributable to general disease progression. Dudeney (10) reported improvements in quality of life as measured with short form-36 (SF-36) at a 7.4-month follow-up, but no mention was made of a longer follow-up period. Eleraky et al. (11) did not report on quality of life, but Oswestry scores were measured to an average follow-up of 16 months and showed clear improvements. As Montagu et al. (32) stated in 2012, there are few reports about the qualities of life of patients with malignant VCFs.

None of our cases died within the first 30 days (21, 32) after surgery; thus retrospective study of the entire group allowed us to reach conclusions about the long-term outcomes of this minimally invasive treatment in well-selected patients with pathological VCFs. None of the deaths that occurred in the course of this study were related to the surgical procedure or the technique. In all cases, these deaths were related to the progression of the primary disease.

Height restoration analyses revealed statistically significant improvements in anterior heights (6.2 mm/31.6%), central heights (5.8 mm/34.7%) and posterior heights (2.4 mm/8.8%). These improvement in vertebral body reduction resulted in Cobb regional angle reductions of 3.2° at postop and 2.9° at the 12-month follow-up. The differences between these values at preop and at every follow-up were statistically significant (p<0.005). Georgy (14) did not evaluate any measures of height in 2012. In a review of the cementoplasty technique in 2011, Aghayev et al. reported significant increases with BKPs between 2-4 mm; although this author suggests that sagittal balance corrections are beneficial in avoiding complications, this review does not report on Cobb angle reductions. Zonglai (41) reported benefits in terms of both height increases greater than 30% (no absolute values are reported) and Cobb angle reduction of approximately 8° at a 2-year follow-up.

The complications can be divided in two groups: short-term (i.e., cement leakages and pulmonary embolisms), and long-term (i.e., adjacent fractures, regional kyphosis, disc degeneration and vertebral body re-collapse). The cement leakage ratios were within the lower margin of the various relevant publications, which range from 4 to 72.5% (4, 8, 10, 11, 14, 24, 32). In our series, none of the leaked cement was located in the spinal canal or the foraminal area. Cement leakage ratios in patients with spinal metastases are typically higher than the quoted ratio due to the osteolysis of the VB in pathological fractures (6, 15, 17, 31, 35). The use of high viscosity cement (400 mPA) and two titanium implants that act as a guiding frame may be the main factors responsible for obtaining a horse-shoe pattern of cement distribution and avoiding high leakage ratios. This finding should be investigated in further cadaveric and clinical studies.

The multidisciplinary approach to the treatment of patients with spinal metastases and greater than 5-year life expectations, particular those patients with hematologic diseases (3,19,20,23), revealed the important role of a minimal invasive technique that controls pain and minimizes biomechanical complications by achieving vertebral body anatomical reduction. This technique can avoid future deformities, new fractures, and long-term increases in pain.

The limitations of our study included its retrospective nature, the consecutive patients, and the absence of a non-reduction control group.

■ CONCLUSION

The present study indicated that anatomical restoration (i.e., cortical ring reduction plus endplate rebalancing) is potentially beneficial to a well-selected group of patients with spine metastases and long life expectancies because it avoids the complications typical of these types of treatments (i.e., leakage, adjacent fractures and re-collapse).

Prospective, blinded, randomized studies could enhance the understanding of the benefits of cementoplasty and vertebral body reduction in the control and management of painful, malignant vertebral body fractures.

■ ACKNOWLEDGMENT

David Cesar NORIEGA and Francisco ARDURA are consultants for Vexim, Antonio KRÜGER is consultant for Vexim, Dfine, Biomet, and Medtronic.

■ REFERENCES
